Form 4 for DXCM Dexcom

Accepted 2026-03-10 00:00:00 ET · period of report 2026-03-08 · accession 0001093557-26-000049 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2026-03-10	2026-03-08	DXCM	Sylvain Jereme M	EVP, Chief Financal Off	A - Grant	$0.00	+48.8K	172.2K	+40%	$0
	2026-03-10	2026-03-08	DXCM	Sylvain Jereme M	EVP, Chief Financal Off	F - Tax	$68.10	-18.9K	153.3K	-11%	-$1.29M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-03-08	A	A	48,774	$0.00	172,242	D	—	—	(F1) Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.
2	Common	Common Stock	2026-03-08	F	D	18,950	$68.10	153,292	D	—	—	(F2) Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. (F3) Included in this number are 92,794 unvested RSUs, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 261 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.